Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group Study D9803

Carola A.S. Arndt, Julie A. Stoner, Douglas S. Hawkins, David A. Rodeberg, Andrea A. Hayes-Jordan, Charles N. Paidas, David M. Parham, Lisa A. Teot, Moody D. Wharam, John C. Breneman, Sarah S. Donaldson, James R. Anderson, William H. Meyer

Research output: Contribution to journal › Article › peer-review

214 Scopus citations

Fingerprint

Dive into the research topics of 'Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group Study D9803'. Together they form a unique fingerprint.

Medicine & Life Sciences